302 related articles for article (PubMed ID: 31020786)
1. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
Nair P; Prado M; Perea-Gil I; Karakikes I
Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
[TBL] [Abstract][Full Text] [Related]
2. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.
Gintant G; Burridge P; Gepstein L; Harding S; Herron T; Hong C; Jalife J; Wu JC
Circ Res; 2019 Oct; 125(10):e75-e92. PubMed ID: 31533542
[TBL] [Abstract][Full Text] [Related]
3. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity.
Liu S; Fang C; Zhong C; Li J; Xiao Q
Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trial in a Dish: Using Patient-Derived Induced Pluripotent Stem Cells to Identify Risks of Drug-Induced Cardiotoxicity.
Lam CK; Wu JC
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1019-1031. PubMed ID: 33472401
[TBL] [Abstract][Full Text] [Related]
6. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Stack JP; Moslehi J; Sayed N; Wu JC
Eur Heart J; 2019 Jun; 40(22):1764-1770. PubMed ID: 29377985
[TBL] [Abstract][Full Text] [Related]
7. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
Tzatzalos E; Abilez OJ; Shukla P; Wu JC
Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
[TBL] [Abstract][Full Text] [Related]
8. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
[TBL] [Abstract][Full Text] [Related]
10. Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes.
Matsui T; Miyamoto K; Yamanaka K; Okai Y; Kaushik EP; Harada K; Wagoner M; Shinozawa T
Toxicol Appl Pharmacol; 2019 Nov; 383():114761. PubMed ID: 31533062
[TBL] [Abstract][Full Text] [Related]
11. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
12. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
13. Stem cells for drug screening.
Laposa RR
J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
Oleaga C; Riu A; Rothemund S; Lavado A; McAleer CW; Long CJ; Persaud K; Narasimhan NS; Tran M; Roles J; Carmona-Moran CA; Sasserath T; Elbrecht DH; Kumanchik L; Bridges LR; Martin C; Schnepper MT; Ekman G; Jackson M; Wang YI; Note R; Langer J; Teissier S; Hickman JJ
Biomaterials; 2018 Nov; 182():176-190. PubMed ID: 30130706
[TBL] [Abstract][Full Text] [Related]
17. Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems.
Magdy T; Schuldt AJT; Wu JC; Bernstein D; Burridge PW
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():83-103. PubMed ID: 28992430
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Huang MF; Pang LK; Chen YH; Zhao R; Lee DF
Cells; 2021 Oct; 10(11):. PubMed ID: 34831045
[TBL] [Abstract][Full Text] [Related]
19. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes.
Karakikes I; Ameen M; Termglinchan V; Wu JC
Circ Res; 2015 Jun; 117(1):80-8. PubMed ID: 26089365
[TBL] [Abstract][Full Text] [Related]
20. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
